Antibodies

Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study 3:08
Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study
Barry Singer • 28 Feb 2023
Impact of natalizumab on chronic active MS lesions 3:33
Impact of natalizumab on chronic active MS lesions
Laura Airas • 16 Feb 2023
Prevention medication for pediatric migraine: should it be re-examined? 8:37
Prevention medication for pediatric migraine: should it be re-examined?
Massimiliano Valeriani • 15 Dec 2022
Update on EHF guideline for anti-CGRP antibodies for migraine prevention 1:26
Update on EHF guideline for anti-CGRP antibodies for migraine prevention
Raffaele Ornello • 5 Dec 2022
Real-world data to enhance migraine clinical trials 2:22
Real-world data to enhance migraine clinical trials
Raffaele Ornello • 5 Dec 2022
Switching erenumab to fremanezumab in chronic migraine: results of a real-world study 1:49
Switching erenumab to fremanezumab in chronic migraine: results of a real-world study
Valeria Caponnetto • 14 Dec 2022
Preliminary data on the use of anti-CGRP mAbs in pediatric migraine 1:30
Preliminary data on the use of anti-CGRP mAbs in pediatric migraine
Massimiliano Valeriani • 15 Dec 2022
Real-world data on anti-CGRP monoclonal antibodies 8:29
Real-world data on anti-CGRP monoclonal antibodies
Gisela Terwindt • 12 Dec 2022
Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS 3:10
Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS
Mar Tintoré • 4 Nov 2022
METEOROID: Phase III trial of satralizumab in patients with MOGAD 2:21
METEOROID: Phase III trial of satralizumab in patients with MOGAD
Kazuo Fujihara • 28 Oct 2022
Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD 5:25
Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD
Kazuo Fujihara • 28 Oct 2022
Unmet needs in the diagnostics and treatment of NMOSD 3:00
Unmet needs in the diagnostics and treatment of NMOSD
Kazuo Fujihara • 28 Oct 2022
New agents under investigation to treat AQP4-positive NMOSD 1:32
New agents under investigation to treat AQP4-positive NMOSD
Kazuo Fujihara • 28 Oct 2022
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS 4:32
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS
João José Cerqueira • 28 Oct 2022
The benefits of immune reconstitution therapy in MS 1:28
The benefits of immune reconstitution therapy in MS
Celia Oreja-Guevara • 28 Oct 2022
Current recommendations on MS treatment during pregnancy 1:46
Current recommendations on MS treatment during pregnancy
Eva Kubala Havrdová • 27 Oct 2022
The content of VJNeurology is intended for healthcare professionals